Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950504 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
A Phase 1 study, sponsored by COUR Pharmaceutical Development Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04950504 is a Phase 1 study that was terminated before completion, run by COUR Pharmaceutical Development Company. The registered enrollment target is 9 participants.
The verdict
NCT04950504, a Phase 1 study, was terminated before completion, sponsored by COUR Pharmaceutical Development Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in Part A, with the goal of identifying a safe and tolerable dose level to be evaluated further in a larger number of subjects in Part B.
Interventions
- DRUG Placebo
- DRUG CNP-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04950504
The ClinicalTrials.gov registry entry for NCT04950504 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is COUR Pharmaceutical Development Company, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04950504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04950504 about?
NCT04950504 is a clinical study titled "Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy". This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in Part A, with the goal of identifying a safe and tolerable dose level to b...
What is the current status of trial NCT04950504?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-06-02. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT04950504?
The interventions under investigation include: Placebo (DRUG), CNP-201 (DRUG).
Who is sponsoring clinical trial NCT04950504?
This trial is sponsored by COUR Pharmaceutical Development Company, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.